These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15290154)

  • 1. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration.
    Augustin AJ; D'Amico DJ; Mieler WF; Schneebaum C; Beasley C
    Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):9-12. PubMed ID: 15290154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Schmidt-Erfurth U; Michels S; Michels R; Aue A
    Eur J Ophthalmol; 2005; 15(4):482-5. PubMed ID: 16001382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger DS; Luna SP; Robertson SM; Russell S; Singerman L; Slakter JS; Yannuzzi L; Zilliox P;
    Ophthalmology; 2003 Dec; 110(12):2372-83; discussin 2384-5. PubMed ID: 14644721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
    Slakter JS; Bochow TW; D'Amico DJ; Marks B; Jerdan J; Sullivan EK; Robertson SM; Slakter JS; Sullins G; Zilliox P;
    Ophthalmology; 2006 Jan; 113(1):3-13. PubMed ID: 16368146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger S; Luna S; Robertson SM; Russell S; Singerman L; Slakter JS; Sullivan EK; Yannuzzi L; Zilliox P;
    Retina; 2003 Feb; 23(1):14-23. PubMed ID: 12652226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration.
    Regillo CD; D'Amico DJ; Mieler WF; Schneebaum C; Beasley CH; Sullins GT
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S70-8. PubMed ID: 17240259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posterior juxtascleral depot administration of anecortave acetate.
    Kaiser PK; Goldberg MF; Davis AA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S62-9. PubMed ID: 17240258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes.
    Russell SR; Hudson HL; Jerdan JA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S79-90. PubMed ID: 17240260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First clinical experience with anecortave acetate (Retaane).
    Hayek S; Scherrer M; Barthelmes D; Fleischhauer JC; Kurz-Levin MM; Menghini M; Helbig H; Sutter FK
    Klin Monbl Augenheilkd; 2007 Apr; 224(4):279-81. PubMed ID: 17458792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study.
    Klais CM; Eandi CM; Ober MD; Sorenson JA; Sadeghi SN; Freund KB; Spaide RF; Slakter JS; Yannuzzi LA
    Retina; 2006 Sep; 26(7):773-9. PubMed ID: 16963850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical efficacy of anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S41-8. PubMed ID: 17240256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation.
    Robin AL; Clark AF; Covert DW; Krueger S; Bergamini MV; Landry TA; Dickerson JE; Scheib SA; Realini T; Defaller JM; Cagle GD
    Am J Ophthalmol; 2009 Jan; 147(1):45-50.e2. PubMed ID: 18789793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and metabolism of anecortave acetate in animals and humans.
    Dahlin DC; Rahimy MH
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S49-61. PubMed ID: 17240257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration.
    Aggermann T; Haas P; Binder S
    Ann Ophthalmol (Skokie); 2008; 40(1):28-30. PubMed ID: 18556978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posterior juxtascleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes.
    Jockovich ME; Murray TG; Clifford PD; Moshfeghi AA
    Retina; 2007 Feb; 27(2):247-52. PubMed ID: 17290209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anecortave acetate.
    Bakri SJ; Kaiser PK
    Expert Opin Investig Drugs; 2006 Feb; 15(2):163-9. PubMed ID: 16433595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anecortave acetate in the treatment of age-related macular degeneration.
    Augustin A
    Clin Interv Aging; 2006; 1(3):237-46. PubMed ID: 18046876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypotensive effect of juxtascleral administration of anecortave acetate in different types of glaucoma.
    Prata TS; Tavares IM; Mello PA; Tamura C; Lima VC; Belfort R
    J Glaucoma; 2010 Sep; 19(7):488-92. PubMed ID: 20051887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study.
    Eandi CM; Ober MD; Freund KB; Klais CM; Slakter JS; Sorenson JA; Yannuzzi LA
    Retina; 2006 Sep; 26(7):780-5. PubMed ID: 16963851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.